Cytodyn Inc (CYDY)

[DonDonDonDon]

Same thing with Le Zulu Mab. Three changes to meet watered down endpoint

HGEN's lenzilumab ended with the same primary endpoint that is started. Not sure how you can call that watered down.

and no inventory ready for a year to treat a minimal amount of patients.

There will be 100,000 treated with lenzilumab in 2021. At $10,000 per treatment, that is $1 billion. In 2022, $10-$20 billion is realistic. Becoming the SOC for hospitalized patients is going to be very lucrative.

The reason Leronlimab will have difficulty getting any approvals in Covid is because the path would show the incompetence of the FDA with their own statements how ridiculous they look. Blood on their hands would be obvious.

The FDA has blood on their hands because they didn't give you approval on 24% efficacy on a 16% slice of the trial? The FDA doesn't give EUAs based on theories or the hopes of its investors.